Targeting HSP70 protein-protein interactions for cancer precision Therapy: Mechanisms, structures, and inhibitor strategies.
1/5 보강
Dysregulated protein homeostasis and aberrant signaling pathways are established hallmarks of cancer.
APA
Li LT, Yang YY, et al. (2026). Targeting HSP70 protein-protein interactions for cancer precision Therapy: Mechanisms, structures, and inhibitor strategies.. European journal of medicinal chemistry, 304, 118552. https://doi.org/10.1016/j.ejmech.2025.118552
MLA
Li LT, et al.. "Targeting HSP70 protein-protein interactions for cancer precision Therapy: Mechanisms, structures, and inhibitor strategies.." European journal of medicinal chemistry, vol. 304, 2026, pp. 118552.
PMID
41483509 ↗
Abstract 한글 요약
Dysregulated protein homeostasis and aberrant signaling pathways are established hallmarks of cancer. Among key molecular players, heat shock protein 70 (HSP70) exerts critical oncogenic functions by forming stable protein-protein interactions (PPIs) with co-chaperones and client proteins, thereby sustaining malignant signaling, suppressing apoptosis, and promoting drug resistance. However, conventional ATPase inhibitors targeting HSP70 face clinical limitations, including target conservation, systemic toxicity, and induction of the heat shock response. Inhibitors targeting HSP70 PPIs demonstrate superior selectivity, reduced toxicity, and enhanced resistance. This review systematically examines the mechanisms through which major HSP70-mediated PPIs drive tumor progression and treatment resistance. Furthermore, we provide structural insights into druggable PPI interfaces localized to the HSP70 nucleotide-binding domain (NBD) and C-terminal TPR-recognition motif, critically evaluating recent advances in the development of small-molecule and peptide-based PPI inhibitors. Together, these analyses offer new perspectives for advancing precision cancer therapeutics.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.